Trial Profile
A Phase II Study of Docetaxel With PI-88 in Patients With Advanced Non-Small-Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Jun 2022
Price :
$35
*
At a glance
- Drugs Muparfostat (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Cellxpert Biotechnology
- 13 Sep 2016 New trial record
- 30 Aug 2016 Status changed from active, no longer recruiting to completed.